Readout technologies for highly miniaturized kinase assays applicable to high-throughput screening in a 1536-well format

Journal of Biomolecular Screening

Volumn 11, Issue 6, 2006, Pages 617-633

  Klumpp, Martin ^a   Boettcher, Andreas ^a   Becker, Damaris ^a   Meder, Gabriele ^a   Blank, Jutta ^a   Leder, Lukas ^a   Forstner, Michael ^a   Ottl, Johannes ^a   Mayr, Lorenz M ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Assay; Chemiluminescence; Fluorescence polarization (FP); High throughput screening (HTS); IMAP; Kinase; Time resolved fluorescence resonance energy transfer (TR FRET)

Indexed keywords

ADENOSINE TRIPHOSPHATE; PHOSPHOTRANSFERASE;

ARTICLE; CHEMOLUMINESCENCE; ENZYME SUBSTRATE; FLUORESCENCE POLARIZATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; PERFORMANCE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

BIOLOGICAL ASSAY; DRUG EVALUATION, PRECLINICAL; FLUORESCENCE POLARIZATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; PARTICLE SIZE; PEPTIDES; PROTEIN KINASES; SUBSTRATE SPECIFICITY;

EID: 33746862782     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057106288444     Document Type: Article

References (38)

1. Cohen P: Protein kinases - the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002;1:309-315.
2. Druker BJ: Imatinib as a paradigm of targeted therapies. Adv Cancer Res 2004;91:1-30.
3. Albanell J, Gascon P: Small molecules with EGFR-TK inhibitor activity. Curr Drug Targets 2005;6:259-274.
4. Riento K, Ridley AJ: ROCKS: Multifunctional kinases in cell behaviour. Nature Rev Mol Cell Biol 2003;4:446-456.
5. Arora A, Scholar EM: Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005;315:971-979.
6. Wesche H, Xiao SH, Young SW: High throughput screening for protein kinase inhibitors. Comb Chem High Throughput Screen 2005;8:181-195.
7. Wu TL, Sun YC, Chang PY, Tsao KC, Sun CF, Wu JT: Establishment of ELISA on 384-well microplate for AFP, CEA, CA 19-9, CA 15-3, CA 125, and PSA-ACT: higher sensitivity and lower reagent cost. J Clin Lab Anal 2003;17:241-246.
8. Beasley JR, McCoy PM, Walker TL, Dunn DA: Miniaturized, ultra-high throughput screening of tyrosine kinases using homogeneous, competitive fluorescence immunoassays. Assay Drug Dev Technol 2004;2:141-151.
9. Kolb AJ, Kaplita PV, Hayes DJ, Park YW, Pernell C, Major JS, et al: Tyrosine kinase assays adapted to homogeneous time-resolved fluorescence. Drug Discov Today 1998;3:333-349.
10. Bazin H, Trinquet E, Mathis G: Time resolved amplification of cryptate emission: a versatile technology to trace biomolecular interactions. J Biotechnol 2002;82:233-250.
11. Lundin K, Blomberg K, Nordstrom T, Lindqvist C: Development of a time-resolved fluorescence resonance energy transfer assay (cell TR-FRET) for protein detection on intact cells. Anal Biochem 2001;299:92-97.
12. Kolb JM, Yamanaka G, Manly SP: Use of a novel homogeneous fluorescent technology in high throughput screening. J Biomol Screen 1996;1:203-210.
13. Burke TJ, Loniello KR, Beebe JA, Ervin KM: Development and application of fluorescence polarization assays in drug discovery. Comb Chem High Throughput Screen 2003;6:183-194.
14. Kowski TJ, Wu JJ: Fluorescence polarization is a useful technology for reagent reduction in assay miniaturization. Comb Chem High Throughput Screen 2000;3:437-433.
15. Seethala R, Menzel R: A homogeneous, fluorescence polarization assay for Src-family tyrosine kinases. Anal Biochem 1997;253:210-218.
16. Seethala R, Menzel R: A fluorescence polarization competition immunoassay for tyrosine kinases. Anal Biochem 1998;255:257-262.
17. Gaudet E, Huang KS, Zhang Y, Huang W, Mark D, Sportsman JR: A homogeneous fluorescence polarization assay adaptable for a range of protein serine/threonine and tyrosine kinases. J Biomol Screen 2003;8:164-175.
18. Sportsman JR, Gaudet E, Boge A: Immobilized metal ion affinity-based fluorescence polarization (IMAP): advances in kinase screening. Assay Drug Dev Technol 2004;2:205-214.
19. Koresawa M, Okabe T: High-throughput screening with quantitation of ATP consumption: a universal non-radioisotope, homogeneous assay for protein kinase. Assay Drug Dev Technol 2004;2:153-160.
20. Cross DAE, Alessi DR, Cohen P, Andejlkovich M, Hemmings BA: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995;378:785-789.
21. Rajkowski KM, Cittanova N: Corrected equations for the calculation of protein-ligand binding results from fluorescence polarization data. J Theor Biol 1981;93:691-696.
22. Cheng Y-C, Prusoff WH: Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099-3108.
23. Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, Graham AG, et al: Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nature Struct Biol 2002;9:268-272.
24. Traut TW: Physiological concentrations of purines and pyrimidines. Mol Cell Biochem 1994;140:1-22.
25. Turek-Etienne TC, Kober TP, Stafford JM, Bryant RW: Development of a fluorescence polarization AKT serine/threonine kinase assay using an immobilized metal ion affinity-based technology. Assay Drug Dev Technol 2004;4:545-553.
26. Loomans EEMG, van Doornmalen AM, Wat JWY, Zaman GJR: High-throughput screening with immobilized metal ion affinity-based fluorescence polarization detection: a homogeneous assay for protein kinases. Assay Drug Dev Technol 2003;1:445-453.
27. Blum G, Gazit A, Levitzki A: Substrate-competitive inhibitors of IGF-1 receptor kinase. Biochemistry 2000;39:15705-15712.
28. Gumireddy K, Baker SJ, Cosenza SC, John P, Kang AD, Robell KA, et al: A non-ATP-competitive inhibitor of BCR-ABE overrides imatinib resistance. Proc Natl Acad Sci U S A 2005;102:1992-1997.
29. Singh P, Lillywhite B, Bannaghan C, Broad P: Using IMAP technology to identify kinase inhibitors: comparison with a substrate depletion approach and analysis of the nature of false positives. Comb Chem High Throughput Screen 2005;8:319-325.
30. Newman M, Josiah S: Utilization of fluorescence polarization and time resolved fluorescence resonance energy transfer assay formats for SAR studies: Src kinase as a model system. J Biomol Screen 2004;9:525-532.
31. Ishida A, Yoshikawa T, Kamidate T: Firefly bioluminescence assay of ATP using diethylaminoethyl-dextran as an enhancer in the presence of sodium chloride and ATP extractant. Anal Biochem 2003;316:127-130.
32. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
33. Beasley JR, Dunn DA, Walker TL, Parlato SM, Lehrach JM, Auld DS: Evaluation of compound interference in immobilized metal ion affinity-based fluorescence polarization detection with a four million member compound collection. Assay Drug Dev Technol 2003;1:455-459.
34. Songyang Z, Blechner S, Hoagland N, Hoekstra MF, Piwnica-Worms H, Cantley LC: Use of an oriented peptide library to determine the optimal substrates of protein kinases. Curr Biol 1994;4:973-982.
35. Schutkowski M, Reimer U, Panse S, Dong L, Lizcano JM, Alessi DR, et al: High-content peptide microarrays for deciphering kinase specificity and biology. Angew Chem 2004;116:2725-2728.
36. Walters WP, Namchuk M: Designing screens: how to make your hits a hit. Nature Rev Drug Discov 2003;2:259-266.
37. Srinivasan J, Cload ST, Hamaguchi N, Kurz J, Keene S, Kurz M, et al: ADP-specific sensors enable universal assay of protein kinase activity. Chem Biol 2004;11:499-508.
38. Brune M, Corrie JET, Webb MR: A fluorescent sensor of the phosphorylation state of nucleoside diphosphate kinase and its use to monitor nucleoside diphosphate concentrations in real time. Biochemistry 2001;40:5087-5094.